
Performant (PFMT) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2024Income Metrics
Revenue
31.5M
Operating Income
-2.1M
-6.82%
Net Income
-2.4M
-7.56%
EPS (Diluted)
$-0.03
Balance Sheet Metrics
Total Assets
101.8M
Total Liabilities
26.6M
Shareholders Equity
75.2M
Debt to Equity
0.35
Cash Flow Metrics
Operating Cash Flow
-1.3M
Free Cash Flow
-2.5M
Revenue & Profitability Trend
Performant Income Statement From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 113.7M | 109.2M | 124.4M | 155.9M | 150.4M |
Cost of Goods Sold | - | - | - | 100.7M | 115.2M |
Gross Profit | - | - | - | 55.3M | 35.2M |
Gross Margin % | 0.0% | 0.0% | 0.0% | 35.5% | 23.4% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 90.4M | 85.3M | 87.4M | 100.7M | 115.2M |
Other Operating Expenses | 29.4M | 30.8M | 38.3M | 42.2M | 47.7M |
Total Operating Expenses | 119.9M | 116.1M | 125.7M | 142.9M | 162.9M |
Operating Income | -6.1M | -6.9M | -1.3M | 13.0M | -12.4M |
Operating Margin % | -5.4% | -6.3% | -1.1% | 8.4% | -8.3% |
Non-Operating Items | |||||
Interest Income | 240.0K | 0 | 0 | 21.0K | 41.0K |
Interest Expense | 2.0M | 1.0M | 11.3M | 7.2M | 7.6M |
Other Non-Operating Income | 3.0K | 1.5M | 2.4M | -27.0M | -7.2M |
Pre-tax Income | -7.9M | -6.4M | -10.2M | -21.2M | -27.2M |
Income Tax | -340.0K | 132.0K | 62.0K | -7.2M | -377.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -7.5M | -6.5M | -10.3M | -14.0M | -26.8M |
Net Margin % | -6.6% | -6.0% | -8.3% | -9.0% | -17.8% |
Key Metrics | |||||
EBITDA | 825.0K | -1.2M | 5.7M | 20.1M | -1.3M |
EPS (Basic) | $-0.10 | $-0.09 | $-0.17 | $-0.26 | $-0.50 |
EPS (Diluted) | $-0.10 | $-0.09 | $-0.17 | $-0.26 | $-0.50 |
Basic Shares Outstanding | 76156000 | 72937000 | 60461000 | 54414000 | 53468000 |
Diluted Shares Outstanding | 76156000 | 72937000 | 60461000 | 54414000 | 53468000 |
Income Statement Trend
Performant Balance Sheet From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 7.3M | 23.4M | 17.3M | 16.0M | 3.4M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 17.6M | 15.8M | 20.8M | 23.2M | 27.2M |
Inventory | - | - | - | - | - |
Other Current Assets | 3.7M | 3.7M | 3.1M | 3.8M | 3.3M |
Total Current Assets | 39.8M | 57.5M | 54.7M | 54.5M | 37.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 531.0K | 2.1M | 3.2M | 5.0M | 6.8M |
Goodwill | 94.7M | 94.7M | 94.7M | 95.4M | 149.7M |
Intangible Assets | - | - | - | 689.0K | 925.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 2.3M | 1.0M | 963.0K | 1.1M | 975.0K |
Total Non-Current Assets | 59.2M | 61.3M | 67.3M | 71.7M | 101.9M |
Total Assets | 99.0M | 118.8M | 122.0M | 126.2M | 138.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 727.0K | 1.3M | 1.1M | 407.0K | 2.5M |
Short-term Debt | 250.0K | 2.2M | 2.4M | 62.3M | 6.1M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 3.0M | 3.4M | 4.9M | 4.9M | 4.6M |
Total Current Liabilities | 12.4M | 14.2M | 17.5M | 77.2M | 19.4M |
Non-Current Liabilities | |||||
Long-term Debt | 5.3M | 19.3M | 20.9M | 3.4M | 63.5M |
Deferred Tax Liabilities | - | - | - | - | 35.0K |
Other Non-Current Liabilities | 648.0K | 881.0K | 1.2M | 3.6M | 1.8M |
Total Non-Current Liabilities | 5.9M | 20.1M | 22.1M | 7.0M | 65.8M |
Total Liabilities | 18.3M | 34.3M | 39.6M | 84.2M | 85.2M |
Equity | |||||
Common Stock | 8.0K | 7.0K | 7.0K | 5.0K | 5.0K |
Retained Earnings | -65.3M | -57.8M | -51.2M | -41.0M | -27.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 80.7M | 84.5M | 82.4M | 42.0M | 53.6M |
Key Metrics | |||||
Total Debt | 5.5M | 21.5M | 23.2M | 65.7M | 69.6M |
Working Capital | 27.4M | 43.3M | 37.2M | -22.7M | 17.6M |
Balance Sheet Composition
Performant Cash Flow Statement From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -7.5M | -6.5M | -10.3M | -14.0M | -26.8M |
Depreciation & Amortization | 6.7M | 5.7M | 7.0M | 7.0M | 11.1M |
Stock-Based Compensation | 3.9M | 3.0M | 2.6M | 2.6M | 2.3M |
Working Capital Changes | -1.3M | -1.6M | -4.1M | -5.3M | -9.7M |
Operating Cash Flow | 2.2M | 710.0K | -1.2M | -8.5M | -23.1M |
Investing Activities | |||||
Capital Expenditures | -4.1M | 1.3M | -3.4M | -3.8M | -4.9M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -4.1M | 1.7M | -270.0K | -3.8M | -4.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 5.0M | 0 | 20.0M | 0 | 21.0M |
Debt Repayment | -19.5M | -500.0K | -60.9M | -3.4M | -2.5M |
Financing Cash Flow | -15.9M | -502.0K | 567.0K | -3.7M | 18.0M |
Free Cash Flow | -283.0K | -6.5M | -2.5M | 17.0M | -20.3M |
Net Change in Cash | -17.8M | 1.9M | -861.0K | -16.0M | -10.0M |
Cash Flow Trend
Performant Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-76.80
Forward P/E
118.67
Price to Book
7.94
Price to Sales
5.19
PEG Ratio
-0.38
Profitability Ratios
Operating Margin
-5.17%
Return on Equity
-9.32%
Return on Assets
-7.59%
Financial Health
Current Ratio
2.67
Debt to Equity
0.12
Per Share Data
EPS (TTM)
$-0.10
Book Value per Share
$0.97
Revenue per Share
$1.49
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
pfmt | 590.7M | -76.80 | 7.94 | -9.32% | 0.00% | 0.12 |
Veeva Systems | 45.3B | 56.76 | 6.82 | 13.70% | 27.29% | 1.29 |
Ge Healthcare | 34.9B | 15.66 | 3.59 | 25.80% | 11.22% | 107.67 |
Certara | 1.8B | 226.40 | 1.70 | 0.75% | 1.97% | 29.00 |
10x Genomics | 1.6B | -8.32 | 2.03 | -11.30% | -13.13% | 11.22 |
Omnicell | 1.5B | 63.66 | 1.17 | 1.87% | 2.01% | 30.42 |
Financial data is updated regularly. All figures are in the company's reporting currency.